Lipoprotein(a): From Molecules to Therapeutics

被引：17

作者：

Bermudez, Valmore ^{[1
]}

Arraiz, Nailet ^{[1
]}

Aparicio, Daniel ^{[1
]}

Rojas, Edward ^{[1
]}

Gotera, Daniela ^{[1
]}

Guerra, Xavier ^{[1
]}

Canelon, Roger ^{[1
]}

Faria, Judith ^{[1
]}

Sorell, Luis ^{[2
]}

Amell, Anilsa ^{[1
]}

Reyna, Nadia ^{[1
]}

Cabrera, Mayela ^{[1
]}

Mengual, Edgardo ^{[1
]}

Cano, Raquel ^{[1
]}

Cano, Climaco ^{[1
]}

Velasco, Manuel ^{[3
]}

机构：

[1] Univ Zulia, Sch Med, Endocrine & Metab Dis Res Ctr, Maracaibo 4004, Venezuela

[2] Genet Engn & Biotechnol Ctr, Angiol & Vasc Surg Inst, Havana, Cuba

[3] Cent Univ Venezuela, Vargas Med Sch, Clin Pharmacol Unit, Caracas, Venezuela

来源：

AMERICAN JOURNAL OF THERAPEUTICS | 2010年 / 17卷 / 03期

关键词：

cardiovascular disease; hyperlipoproteinemia(a); lipoprotein(a); atherogenesis; therapeutics; CORONARY-HEART-DISEASE; LP(A) LIPOPROTEIN; RISK-FACTOR; APOLIPOPROTEIN(A) SIZE; VASCULAR-DISEASE; GROWTH-HORMONE; NICOTINIC-ACID; LIPID PROFILE; L-CARNITINE; E GENOTYPE;

D O I：

10.1097/MJT.0b013e3181e00bf1

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Lipoprotein (a) [Lp(a)] was discovered by Kare Berg in 1963 from the study of low-density lipoprotein genetic variants. Lp(a) contains a unique protein, apolipoprotein(a), which is linked to the Apo B-100 through a disulfide bond that gives it a great structural homology with plasminogen, and confers it atherogenic and atherothrombotic properties. Interest in Lp(a) has increased because an important association between high plasma levels of Lp(a) and coronary artery disease and cerebral vascular disorders has been demonstrated. Numerous case control studies have confirmed that hyper-Lp(a) is a risk factor for premature cardiovascular disease. Lp(a) is identified as a genetic trait with autosomal transmission, codified by one of the most studied polymorphic genes in humans. It has been demonstrated that variations in this gene are a major factor in the serum levels of Lp(a). Variations differ considerably between individuals and sex across populations. Various approaches to drug treatment using fibric acid derivatives, growth hormone, insulin-like growth factor-1, alcohol extracted soy protein, niacin, and exercise have been proven to decrease Lp(a) in high risk patients, but none has really been an effective therapeutic option for successfully reducing Lp(a) plasma levels.

引用

页码：263 / 273

页数：11

共 101 条

[11] THE LP SYSTEM - MANUFACTURING OF ANTISERUM, TESTING METHODS, RESULTS
BERG, K
WENDT, GG
[J]. HUMANGENETIK, 1964, 1 (01): : 24 - 30
[12] BERGLUND L, 2004, ARTERIOSCLER THROMB, V24, P2226
[13] Pirela VB, 2007, AN MED INTERN, V24, P324
[14] Bermúdez V, 2008, REV LATINOAM HIPERTE, V3, P66
[15] Expression of a recombinant apolipoprotein(a) in HepG2 cells - Evidence for intracellular assembly of lipoprotein(a)
Bonen, DK
Hausman, AML
Hadjiagapiou, C
Skarosi, SF
Davidson, NO
[J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (09) : 5659 - 5667
[16] Boraita A, 2004, REV ESP CARDIOL, V57, P495, DOI 10.1016/S1885-5857(06)60624-5
[17] CYS4057 OF APOLIPOPROTEIN(A) IS ESSENTIAL FOR LIPOPROTEIN(A) ASSEMBLY
BRUNNER, C
KRAFT, HG
UTERMANN, G
MULLER, HJ
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (24) : 11643 - 11647
[18] Lipoprotein [a] is cleared from the plasma primarily by the liver in a process mediated by apolipoprotein [a]
Cain, WJ
Millar, JS
Himebauch, AS
Tietge, UJF
Maugeais, C
Usher, D
Rader, DJ
[J]. JOURNAL OF LIPID RESEARCH, 2005, 46 (12) : 2681 - 2691
[19] PRONOUNCED LOWERING OF SERUM LEVELS OF LIPOPROTEIN LP(A) IN HYPERLIPEMIC SUBJECTS TREATED WITH NICOTINIC-ACID
CARLSON, LA
HAMSTEN, A
ASPLUND, A
[J]. JOURNAL OF INTERNAL MEDICINE, 1989, 226 (04) : 271 - 276
[20] Cheesman EJ, 2000, J BIOL CHEM, V275, P28195

← 1 2 3 4 5 6 7 8 9 10 →